AN2 Therapeutics, Inc.
ANTX
$0.03
Change (1 day)
$22.22
Year High
$0.87
Year Low
Categories
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
Revenue of AN2 Therapeutics, Inc. (ANTX)
Revenue in 2023 (TTM): $
According to AN2 Therapeutics, Inc.'s latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of AN2 Therapeutics, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $ | $ | $4.9 M | $-64,732,000 | $-64,732,000 |
| 2022 | $ | $-77,000 | $-42,262,000 | $-40,956,000 | $-41,470,000 |
| 2021 | $ | $ | $-21,574,000 | $-21,543,000 | $-21,474,000 |
| 2020 | $ | $ | $-7,284,000 | $-13,603,000 | $-13,600,000 |
| 2019 | $ | $ | $-5,178,000 | $-5,635,000 | $-5,635,000 |